Avanafil in treatment of post-surgical ED for men with localized prostate cancer

Data published on line in the Journal of Urology last December suggest that the new PDE5 inhibitor known as avanafil or Stendra® is supposedly effective in combating erectile dysfunction (ED) in just over one-third of men with ED at 6 months after bilateral, nerve-sparing radical prostatectomy. … READ MORE …

Avanafil shows benefit against ED in prostate cancer patients post-surgery

According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …

Avanafil shows highly positive results in Phase 3 trial for ED

According to a company press release issued earlier today by VIVUS, Inc., avanafil, an investigational agent, was effective in the treatment of erectile dysfunction (ED) in some 77 percent of patients at a dose of 200 mg. … READ MORE …

The Friday news reports (Part A): February 13, 2009

After a relatively quiet news period, the flood gates have opened again, so we shall divide today’s news reports into two postings for easier reading. We have also published a separate report on the possibility of an association between alcohol use and prostate cancer diagnosis. … READ MORE …